Jane Street Group LLC decreased its stake in Amedisys Inc (NASDAQ:AMED) by 77.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,444 shares of the health services provider’s stock after selling 15,556 shares during the period. Jane Street Group LLC’s holdings in Amedisys were worth $227,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in AMED. Great West Life Assurance Co. Can increased its stake in Amedisys by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock valued at $2,045,000 after buying an additional 2,960 shares in the last quarter. Monarch Partners Asset Management LLC acquired a new stake in shares of Amedisys during the first quarter valued at approximately $8,984,000. First Midwest Bank Trust Division boosted its stake in shares of Amedisys by 3.0% in the first quarter. First Midwest Bank Trust Division now owns 34,740 shares of the health services provider’s stock valued at $1,775,000 after buying an additional 1,012 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after buying an additional 15,875 shares during the last quarter. Finally, State of Alaska Department of Revenue boosted its stake in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares during the last quarter. 97.66% of the stock is currently owned by institutional investors.
Amedisys Inc (NASDAQ:AMED) opened at 61.35 on Monday. Amedisys Inc has a 1-year low of $34.58 and a 1-year high of $65.91. The company has a 50 day moving average of $61.38 and a 200 day moving average of $51.88. The firm has a market capitalization of $2.07 billion, a PE ratio of 45.44 and a beta of 0.94.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, May 2nd. The health services provider reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.06. Amedisys had a net margin of 3.16% and a return on equity of 12.60%. The firm had revenue of $370.46 million for the quarter, compared to analyst estimates of $370.03 million. During the same period last year, the firm posted $0.33 EPS. Analysts forecast that Amedisys Inc will post $2.07 EPS for the current year.
WARNING: This piece was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.wkrb13.com/markets/2284903/amedisys-inc-amed-stake-decreased-by-jane-street-group-llc.html.
Several brokerages have commented on AMED. Stephens lifted their price objective on shares of Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research note on Thursday, May 4th. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. Mizuho upgraded shares of Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective for the company in a research note on Wednesday, May 3rd. Royal Bank of Canada restated a “hold” rating and set a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Finally, Jefferies Group LLC restated a “buy” rating and set a $57.00 price objective on shares of Amedisys in a research note on Friday, April 28th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $58.38.
In related news, insider Scott G. Ginn sold 23,828 shares of Amedisys stock in a transaction on Monday, May 8th. The shares were sold at an average price of $58.62, for a total value of $1,396,797.36. Following the transaction, the insider now directly owns 13,018 shares in the company, valued at approximately $763,115.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Lawrence R. Pernosky sold 11,500 shares of the firm’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $58.97, for a total value of $678,155.00. Following the completion of the sale, the insider now directly owns 30,093 shares of the company’s stock, valued at approximately $1,774,584.21. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,828 shares of company stock worth $3,350,922. 2.80% of the stock is currently owned by insiders.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284903/amedisys-inc-amed-stake-decreased-by-jane-street-group-llc.html
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.